---
document_datetime: 2025-11-23 11:01:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/veltassa.html
document_name: veltassa.html
version: success
processing_time: 0.1074025
conversion_datetime: 2025-12-27 16:44:21.694527
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Veltassa

[RSS](/en/individual-human-medicine.xml/65516)

##### Authorised

This medicine is authorised for use in the European Union

patiromer

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Veltassa](#news-on)
- [More information on Veltassa](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Veltassa is a medicine used for treating adults and adolescents aged 12 years and above with high levels of potassium in the blood (hyperkalaemia). Hyperkalaemia can cause serious heart problems and muscle weakness.

Veltassa contains the active substance patiromer.

Expand section

Collapse section

## How is Veltassa used?

Veltassa is available as sachets containing a powder for mixing with water, liquid or soft food and is to be taken by mouth once daily. The recommended starting dose depends on the patient's age; the dose is adjusted based on the patient's blood levels of potassium.

The medicine can only be obtained with a prescription. For more information about using Veltassa, see the package leaflet or contact your doctor or pharmacist.

## How does Veltassa work?

When Veltassa is taken by mouth, the active substance, patiromer, remains in the gut where it attaches tightly to potassium to form a compound that is then passed out in the stool. In this way, patiromer draws potassium from the body into the gut and so reduces the amount of potassium in the blood.

## What benefits of Veltassa have been shown in studies?

One main study involving adults with chronic kidney disease who had hyperkalaemia found that Veltassa is effective in reducing potassium levels in the blood.

In the first part of the study, 243 patients with hyperkalaemia (with an average potassium level of 5.6 mmol/litre) were treated with Veltassa. After 4 weeks of treatment, their potassium level fell on average by 1.0 mmol/litre.

The second part of the study compared Veltassa with placebo (a dummy treatment) in 107 patients whose potassium level had fallen with Veltassa during the first part of the study. After 4 weeks, the average potassium level did not change in patients who received Veltassa but it went back up by an average of 0.7 mmol/litre in patients who received placebo.

Another study involved 14 adolescents aged 12 years and above with hyperkalaemia (with an average potassium level of 5.5 mmol/litre). After 14 days of treatment with Veltassa, their potassium levels fell on average by 0.5 mmol/litre. This effect persisted, leading to an average reduction by 1.1 mmol/litre after 26 weeks of treatment.

## What are the risks associated with Veltassa?

For the full list of side effects and restrictions with Veltassa, see the package leaflet. The most common side effects with Veltassa (which may affect up to 1 in 10 people) include constipation, diarrhoea, abdominal (belly) pain, wind and low levels of magnesium in the blood.

## Why is Veltassa authorised in the EU?

The European Medicines Agency decided that Veltassa's benefits are greater than its risks and it can be authorised for use in the EU. The Agency considered that there is a need for effective treatment of hyperkalaemia and Veltassa achieves a meaningful lowering of potassium levels. The side effects are relatively moderate but the doctor should take them into account when considering treatment with Veltassa.

## What measures are being taken to ensure the safe and effective use of Veltassa?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Veltassa have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Veltassa are continuously monitored. Suspected side effects reported with Veltassa are carefully evaluated and any necessary action taken to protect patients.

## Other information about Veltassa

Veltassa received a marketing authorisation valid throughout the EU on 19 July 2017.

Veltassa : EPAR - Medicine overview

Reference Number: EMA/580223/2023

English (EN) (117.13 KB - PDF)

**First published:** 01/08/2017

**Last updated:** 16/01/2024

[View](/en/documents/overview/veltassa-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-811)

български (BG) (138.42 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/bg/documents/overview/veltassa-epar-medicine-overview_bg.pdf)

español (ES) (116.26 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/es/documents/overview/veltassa-epar-medicine-overview_es.pdf)

čeština (CS) (136.75 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/cs/documents/overview/veltassa-epar-medicine-overview_cs.pdf)

dansk (DA) (115.5 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/da/documents/overview/veltassa-epar-medicine-overview_da.pdf)

Deutsch (DE) (118.63 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/de/documents/overview/veltassa-epar-medicine-overview_de.pdf)

eesti keel (ET) (115.61 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/et/documents/overview/veltassa-epar-medicine-overview_et.pdf)

ελληνικά (EL) (136.66 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/el/documents/overview/veltassa-epar-medicine-overview_el.pdf)

français (FR) (117.27 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/fr/documents/overview/veltassa-epar-medicine-overview_fr.pdf)

hrvatski (HR) (136.66 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/hr/documents/overview/veltassa-epar-medicine-overview_hr.pdf)

italiano (IT) (115.43 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/it/documents/overview/veltassa-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (143.56 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/lv/documents/overview/veltassa-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (137.32 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/lt/documents/overview/veltassa-epar-medicine-overview_lt.pdf)

magyar (HU) (136.54 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/hu/documents/overview/veltassa-epar-medicine-overview_hu.pdf)

Malti (MT) (140.57 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/mt/documents/overview/veltassa-epar-medicine-overview_mt.pdf)

Nederlands (NL) (116.33 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/nl/documents/overview/veltassa-epar-medicine-overview_nl.pdf)

polski (PL) (138.35 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/pl/documents/overview/veltassa-epar-medicine-overview_pl.pdf)

português (PT) (117.63 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/pt/documents/overview/veltassa-epar-medicine-overview_pt.pdf)

română (RO) (135.16 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/ro/documents/overview/veltassa-epar-medicine-overview_ro.pdf)

slovenčina (SK) (137.59 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/sk/documents/overview/veltassa-epar-medicine-overview_sk.pdf)

slovenščina (SL) (135.14 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/sl/documents/overview/veltassa-epar-medicine-overview_sl.pdf)

Suomi (FI) (113.82 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/fi/documents/overview/veltassa-epar-medicine-overview_fi.pdf)

svenska (SV) (114.86 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

16/01/2024

[View](/sv/documents/overview/veltassa-epar-medicine-overview_sv.pdf)

Veltassa : EPAR - Risk management plan

English (EN) (1.25 MB - PDF)

**First published:** 16/01/2024

[View](/en/documents/rmp/veltassa-epar-risk-management-plan_en.pdf)

## Product information

Veltassa : EPAR - Product Information

English (EN) (320.5 KB - PDF)

**First published:** 01/08/2017

**Last updated:** 11/06/2024

[View](/en/documents/product-information/veltassa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-734)

български (BG) (499.95 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/bg/documents/product-information/veltassa-epar-product-information_bg.pdf)

español (ES) (308.11 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/es/documents/product-information/veltassa-epar-product-information_es.pdf)

čeština (CS) (420.74 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/cs/documents/product-information/veltassa-epar-product-information_cs.pdf)

dansk (DA) (325.6 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/da/documents/product-information/veltassa-epar-product-information_da.pdf)

Deutsch (DE) (350.24 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/de/documents/product-information/veltassa-epar-product-information_de.pdf)

eesti keel (ET) (259.77 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/et/documents/product-information/veltassa-epar-product-information_et.pdf)

ελληνικά (EL) (397.4 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/el/documents/product-information/veltassa-epar-product-information_el.pdf)

français (FR) (324.29 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/fr/documents/product-information/veltassa-epar-product-information_fr.pdf)

hrvatski (HR) (437.78 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/hr/documents/product-information/veltassa-epar-product-information_hr.pdf)

íslenska (IS) (356.64 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/is/documents/product-information/veltassa-epar-product-information_is.pdf)

italiano (IT) (285.44 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/it/documents/product-information/veltassa-epar-product-information_it.pdf)

latviešu valoda (LV) (472.3 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/lv/documents/product-information/veltassa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (468.19 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/lt/documents/product-information/veltassa-epar-product-information_lt.pdf)

magyar (HU) (410.35 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/hu/documents/product-information/veltassa-epar-product-information_hu.pdf)

Malti (MT) (464.97 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/mt/documents/product-information/veltassa-epar-product-information_mt.pdf)

Nederlands (NL) (326.34 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/nl/documents/product-information/veltassa-epar-product-information_nl.pdf)

norsk (NO) (407.91 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/no/documents/product-information/veltassa-epar-product-information_no.pdf)

polski (PL) (493.49 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/pl/documents/product-information/veltassa-epar-product-information_pl.pdf)

português (PT) (328.6 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/pt/documents/product-information/veltassa-epar-product-information_pt.pdf)

română (RO) (450.73 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/ro/documents/product-information/veltassa-epar-product-information_ro.pdf)

slovenčina (SK) (483.49 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/sk/documents/product-information/veltassa-epar-product-information_sk.pdf)

slovenščina (SL) (445.02 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/sl/documents/product-information/veltassa-epar-product-information_sl.pdf)

Suomi (FI) (392.54 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/fi/documents/product-information/veltassa-epar-product-information_fi.pdf)

svenska (SV) (350.63 KB - PDF)

**First published:**

01/08/2017

**Last updated:**

11/06/2024

[View](/sv/documents/product-information/veltassa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0034/G 06/06/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Veltassa: EPAR - All authorised presentations

English (EN) (18.94 KB - PDF)

**First published:** 21/02/2024

[View](/en/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-862)

български (BG) (45.13 KB - PDF)

**First published:**

21/02/2024

[View](/bg/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_bg.pdf)

español (ES) (49.87 KB - PDF)

**First published:**

21/02/2024

[View](/es/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (40.03 KB - PDF)

**First published:**

21/02/2024

[View](/cs/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (23.45 KB - PDF)

**First published:**

21/02/2024

[View](/da/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (27.46 KB - PDF)

**First published:**

21/02/2024

[View](/de/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (19.69 KB - PDF)

**First published:**

21/02/2024

[View](/et/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (43.94 KB - PDF)

**First published:**

21/02/2024

[View](/el/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_el.pdf)

français (FR) (23.62 KB - PDF)

**First published:**

21/02/2024

[View](/fr/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (37.27 KB - PDF)

**First published:**

21/02/2024

[View](/hr/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (23.39 KB - PDF)

**First published:**

21/02/2024

[View](/is/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (19.33 KB - PDF)

**First published:**

21/02/2024

[View](/it/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (45.64 KB - PDF)

**First published:**

21/02/2024

[View](/lv/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (41.55 KB - PDF)

**First published:**

21/02/2024

[View](/lt/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (46.92 KB - PDF)

**First published:**

21/02/2024

[View](/hu/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (44.26 KB - PDF)

**First published:**

21/02/2024

[View](/mt/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.17 KB - PDF)

**First published:**

21/02/2024

[View](/nl/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (23.55 KB - PDF)

**First published:**

21/02/2024

[View](/no/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_no.pdf)

polski (PL) (49.24 KB - PDF)

**First published:**

21/02/2024

[View](/pl/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_pl.pdf)

português (PT) (43.42 KB - PDF)

**First published:**

21/02/2024

[View](/pt/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_pt.pdf)

română (RO) (70.5 KB - PDF)

**First published:**

21/02/2024

[View](/ro/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (44.58 KB - PDF)

**First published:**

21/02/2024

[View](/sk/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (42.74 KB - PDF)

**First published:**

21/02/2024

[View](/sl/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (23.75 KB - PDF)

**First published:**

21/02/2024

[View](/fi/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (23.74 KB - PDF)

**First published:**

21/02/2024

[View](/sv/documents/all-authorised-presentations/veltassa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Veltassa Active substance patiromer sorbitex calcium International non-proprietary name (INN) or common name patiromer Therapeutic area (MeSH) Hyperkalemia Anatomical therapeutic chemical (ATC) code V03AE09

### Pharmacotherapeutic group

Drugs for treatment of hyperkalemia and hyperphosphatemia

### Therapeutic indication

Veltassa is indicated for the treatment of hyperkalaemia in adults and adolescents aged 12 to 17 years.

## Authorisation details

EMA product number EMEA/H/C/004180 Marketing authorisation holder

Vifor Fresenius Medical Care Renal Pharma France

100-101 Terrasse Boieldieu

Opinion adopted 18/05/2017 Marketing authorisation issued 19/07/2017 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Veltassa : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (222.71 KB - PDF)

**First published:** 19/06/2019

**Last updated:** 11/06/2024

[View](/en/documents/procedural-steps-after/veltassa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Veltassa-H-C-004180-X-0031-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/534744/2023

English (EN) (1.91 MB - PDF)

**First published:** 16/01/2024

[View](/en/documents/variation-report/veltassa-h-c-004180-x-0031-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Veltassa (X-31-G)

Adopted

Reference Number: EMA/CHMP/331542/2023

English (EN) (120.47 KB - PDF)

**First published:** 10/11/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-veltassa-x-31-g_en.pdf)

## Initial marketing authorisation documents

Veltassa : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/424270/2017

English (EN) (1.53 MB - PDF)

**First published:** 01/08/2017

**Last updated:** 01/08/2017

[View](/en/documents/assessment-report/veltassa-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Veltassa

Adopted

Reference Number: EMA/CHMP/293038/2017

English (EN) (67.42 KB - PDF)

**First published:** 19/05/2017

**Last updated:** 19/05/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-veltassa_en.pdf)

#### News on Veltassa

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023) 10/11/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 May 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-may-2017) 19/05/2017

#### More information on Veltassa

- [EMEA-001720-PIP01-14-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001720-pip01-14-m04)
- [Non-Interventional, Exploratory, Phase IV, Single-Blind, Cross-Sectional, Randomised, Cross-over Study Evaluating Patient Palatability and Preference of 3 Potassium Binders, Sodium Polystyrene Sulphonate (SPS) or Calcium Polystyrene Sulphonate (CPS), Sodium Zirconium Cyclosilicate (Lokelma®), and Calcium Patiromer Sorbitex (Veltassa®) in Patients with Chronic Kidney Disease and Hyperkalaemia (APPETIZE) - post-authorisation study](https://catalogues.ema.europa.eu/study/49737)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 11/06/2024

## Share this page

[Back to top](#main-content)